

Title (en)
MODIFIED TRANSFERRIN FUSION PROTEINS

Title (de)
FUSIONSPROTEINE MIT MODIFIZIERTEM TRANSFERRIN

Title (fr)
PROTEINES DE FUSION DE TRANSFERRINE MODIFIEES

Publication
EP 1611093 A4 20060628 (EN)

Application
EP 03749159 A 20030828

Priority
• US 0326818 W 20030828
• US 40697702 P 20020830
• US 37809403 A 20030304

Abstract (en)
[origin: US2003221201A1] Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

IPC 8 full level
A61K 38/16 (2006.01); **A61K 38/40** (2006.01); **A61K 38/41** (2006.01); **A61K 47/48** (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01); **C07K 14/705** (2006.01); **C07K 14/79** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP US)
A61K 47/644 (2017.07 - EP US); **A61P 3/10** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **C07K 7/06** (2013.01 - EP US); **C07K 7/08** (2013.01 - EP US); **C07K 14/005** (2013.01 - EP US); **C07K 14/47** (2013.01 - EP US); **C07K 14/565** (2013.01 - EP US); **C07K 14/79** (2013.01 - EP US); **A01K 2217/05** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **C07K 2319/00** (2013.01 - EP US); **C07K 2319/035** (2013.01 - EP US); **C12N 2740/16122** (2013.01 - EP US)

Citation (search report)
• [PX] WO 03020746 A1 20030313 - BIOREXIS PHARMACEUTICAL CORP [US], et al
• [E] WO 2004020404 A2 20040311 - BIOREXIS PHARMACEUTICAL CORP [US], et al
• [E] WO 2004020454 A2 20040311 - BIOREXIS PHARMACEUTICAL CORP [US], et al
• [E] WO 2004020588 A2 20040311 - BIOREXIS PHARMACEUTICAL CORP [US], et al
• [A] ALI S A ET AL: "Transferrin trojan horses as a rational approach for the biological delivery of therapeutic peptide domains", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM, US, vol. 274, no. 34, 20 August 1999 (1999-08-20), pages 24066 - 24073, XP008052346, ISSN: 0021-9258
• [A] PARK E ET AL: "Production and characterization of fusion proteins containing transferrin and nerve growth factor", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 6, no. 1, 1998, pages 53 - 64, XP002960815, ISSN: 1061-186X
• [A] PARISE F ET AL: "Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 10, no. 7, 1 May 1999 (1999-05-01), pages 1219 - 1228, XP009057500, ISSN: 1043-0342
• See references of WO 2004020405A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
US 2003221201 A1 20031127; US 7176278 B2 20070213; AU 2003268208 A1 20040319; AU 2003268208 B2 20090423; BR 0314092 A 20060328; CA 2495210 A1 20040311; DK 1611093 T3 20150928; EP 1611093 A2 20060104; EP 1611093 A4 20060628; EP 1611093 B1 20150715; ES 2547925 T3 20151009; IL 166750 A0 20060115; US 2007050855 A1 20070301; US 2007066813 A1 20070322; WO 2004020405 A2 20040311; WO 2004020405 A3 20050901

DOCDB simple family (application)
US 37809403 A 20030304; AU 2003268208 A 20030828; BR 0314092 A 20030828; CA 2495210 A 20030828; DK 03749159 T 20030828; EP 03749159 A 20030828; ES 03749159 T 20030828; IL 16675005 A 20050208; US 0326818 W 20030828; US 50409906 A 20060815; US 51543003 A 20030828